Recruiting Clinical Trials

Please contact our clinical trial director, Allison Calvanese at (727) 498-6176.

Recruiting Clinical Trials

Wet Age-Related Macular Degeneration

OPT-302-1005 Coast Study (NCT04757636) - A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

KSI301P107 Daylight Study (NCT04964089) - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular Age-related Macular Degeneration (nAMD)

ML43000 Belvedere Study (NCT04853251) - A Phase IV, Open-Label Study of the Response to Treatment after Transition to the Port Delivery System with Ranibizumab (SUSVIMO) in Patients with Neovascular Age-Related Macular Degeneration previously treated with intravitreal agents other than Ranibizumab

RGX-314-2103 Bioreactor Study (NCT04832724) - A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered via Subretinal Delivery in Participants with Neovascular Age-related Macular Degeneration

RGX-314-2104 Atmosphere Study (NCT04704921) - A Randomized, Partially Masked, Controlled, Phase2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

UBX1325-03 Unity Study (NCT04537884) - A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration

BP41670 Burgundy Study (NCT04567303) - A Two-Part, Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7250284 Following Intravitreal Administration of Unmasked Multiple Ascending Doses and Masked Sustained Delivery From The Port Delivery System in Patients with Neovascular Age-Related Macular Degeneration

Diabetic Macular Edema

BP43445 Alluvium Study (NCT05151731)- A Phase II, Double Masked, Active Comparator Controlled Study to Investigate the Efficacy,Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Diabetic Macular Edema

Diabetic Retinopathy

BP41321 Canberra Study (NCT04265261)- A Randomized, 48-Week, Placebo-Controlled Study to Investigate the Efficacy and Safety of RG7774 in Patients with Treatment Naive Diabetic Retinopathy

Uveitis

010906IN Lumina Study (NCT03711929) - A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study (12 months) Assessing the Efficacy and Safety of Intravitreal Injections of 440 μg DE-109 (Sirolimis) for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

BP40899 Dovetail Study - A Phase I, Open-Label, Multiple Ascending Dose Study to Investigator the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of RO7200220 in Monotherapy and in Combination with Ranibizumab in Patients with Diabetic or Uveitic Macular Edema

Dry Age-Related Macular Degeneration

GTSCOPE (NCT03894020) - A Study of Disease Progression in Genetically Defined Subjects with GA Secondary to Age-Related Macular Degeneration

GT005-02 Explore Study (NCT04437368) - A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

GT005-03 Horizon Study (NCT04566445) - A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

GT005-01 Focus Study (NCT03846193) - First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Ionis Study Golden Study ISIS 696844 – CS5 (NCT03815825) - Phase 2, Randomized, Placebo-Controlled, Double-Masked Study (57 weeks) to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX

GR40973 GAllego Study (NCT03972709) - A Phase II, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163

Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, and Diabetic Macular Edema

DETeR Study (NCT04563299) - Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections